In diabetic hyperglycemia, rest-phase orexin antagonism (e.g., suvorexant) suppresses pathological gluconeogenesis and inflammation, offering a dual-benefit strategy improving glycemia while preserving sleep, ideal for nocturnal hepatic overactivity in type 2 diabetes. The gene discussed is HCRT; the disease is type 2 diabetes mellitus.